TMT1A (thiol methyltransferase 1A) is a SAM-dependent methyltransferase that catalyzes S-methylation of exogenous thiol-containing substrates, including clinically relevant drugs like spironolactone, mertansine, and romidepsin 1. The enzyme is localized to the endoplasmic reticulum and exhibits substrate specificity for alkyl and phenolic thiols 1. TMT1A's methyltransferase activity is highly conserved across species (85.7% amino acid identity with mouse, 84.8% with rat, 60.7% with chicken, 51.0% with zebrafish), and all homologs confer resistance to thiol-based histone deacetylase inhibitors (HDACis) by inactivating these drugs through methylation 23. Beyond drug metabolism, TMT1A regulates hydrogen sulfide (H2S) homeostasis by converting H2S to methanethiol, thereby controlling endogenous gasotransmitter levels 4. In cardiac physiology, TMT1A suppression during hypertrophy allows H2S accumulation, which attenuates pathological hypertrophic signaling through AMPK and MAPK pathway modulation 4. TMT1A's dual roles in drug detoxification and H2S metabolism suggest therapeutic potential in both cancer resistance mechanisms and cardiovascular diseases.